BCR::ABL1 F317L resistance mutation
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-BCR-ABL1-F317L |
|---|---|
| Type | Biomarker |
| Aliases | ABL1 p.F317LBCR-ABL F317LBCR-ABL1 F317L resistance mutationBCR::ABL1 F317L — мутація резистентності |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ELN-CML-2020 SRC-ELN-CML-2025 SRC-ESMO-CML-2017 |
Biomarker Facts
| Biomarker type | gene_mutation |
|---|---|
| Mutation details | {"exon": "6", "functional_impact": "partial dasatinib resistance; nilotinib, bosutinib, ponatinib retain activity", "gene": "ABL1", "hgvs_protein": "p.F317L", "variant_type": "missense"} |
| Measurement | MethodBCR::ABL1 kinase-domain Sanger sequencing OR targeted NGS at TKI failure Unitscategorical (positive | negative); VAF % when NGS |
| Actionability lookup | {"gene": "ABL1", "variant": "F317L"} |
| Related biomarkers | BIO-BCR-ABL1 BIO-BCR-ABL1-T315I BIO-BCR-ABL1-V299L |
Notes
Dasatinib-resistance mutation in the ABL1 P-loop region. IC50 for dasatinib elevated ~5-10x, sufficient for clinical resistance at standard 100 mg QD dosing. Nilotinib, bosutinib, and ponatinib retain in-vitro activity and clinical efficacy. Per ELN-2020 / ELN- 2025: detection on dasatinib failure → switch to nilotinib OR bosutinib (asciminib also active). Less common than T315I but a classical TKI-specific resistance pattern that informs sequential TKI selection rather than absolute resistance.
Used By
Biomarker
BIO-BCR-ABL1-T315I- BCR::ABL1 T315I gatekeeper mutationBIO-BCR-ABL1-V299L- BCR::ABL1 V299L dasatinib-resistance mutation